Pancreatic Cancer Treatments Poised for Major Advances in 2024
FN Media Group Presents USA News Group News Commentary
VANCOUVER, BC, Feb. 7, 2024 /PRNewswire/ — USA News Group – One of the more worrying storylines of 2023 was the rising incidence of early-onset pancreatic cancer. As well, the deadly disease showed pancreatic cancer rates rising faster among women, causing increased alarm amongst doctors. Thankfully, 2023 also gave a lot of hope in terms of new treatments for the market that could reach US$36 billion by 2036, such as a potential mRNA vaccine, and other developments from biotech companies to lead into 2024, like Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC), Incyte Corporation (NASDAQ:INCY), Tango Therapeutics, Inc. (NASDAQ:TNGX), RayzeBio, Inc. (NASDAQ:RYZB) and its buyer Bristol-Myers Squibb Company (NYSE:BMY).
Related news for (ONCY)
- Oncolytics Biotech® Files Circular/Prospectus for Special Meeting of Shareholders To Change Jurisdiction of Incorporation to Nevada
- 24/7 Market News Snapshot 29 September, 2025 – Oncolytics Biotech, Inc. Common Shares (NASDAQ:ONCY)
- Oncolytics Biotech® Announces Update for Potential First-Line Pancreatic Cancer Registration Study
- Oncolytics Biotech® Provides Update on GOBLET Study Progress and U.S. Site Expansion
- MoBot alert highlights: NASDAQ: TLPH, NASDAQ: DUO, NASDAQ: INHD, NASDAQ: INVZ, NASDAQ: ONCY (09/08/25 10:00 AM)